TY - JOUR
T1 - Erratum
T2 - The roles of T-cell competition and stochastic extinction events in CAR T-cell therapy (Proceedings of the Royal Society B (2021) 288 (20210229) DOI: 10.1098/rspb.2021.0229)
AU - Kimmel, Gregory J.
AU - Locke, Frederick L.
AU - Altrock, Philipp M.
N1 - Publisher Copyright:
© 2022 Royal Society Publishing. All rights reserved.
PY - 2022
Y1 - 2022
N2 - The published manuscript ‘The roles of T-cell competition and stochastic extinction events in chimaeric antigen receptor T-cell therapy’. [1] requires a correction. For the calculation of initial tumour size, we used data from the literature, specifically as reported by Dean et al. [2]. We inadvertently cited the wrong source (‘[5]’ in the originally published manuscript), which might be of importance for readers in two places in our manuscript. First, in the caption for figure 1, panel (c), on page 3: Median initial tumour mass was 94.86 ml; this median value originates from the combined cohort previously published in Dean et al. [1]. Only 22 patients of this dataset (out of 96) were on the Zuma-1 trial. All others received commercial CAR T cell therapy. Second, in the bottom line of table 1, on page 4, for ‘initial median tumour cell number’, the reference in the last column should have cited the additional reference Dean et al. [2]. Of note, this error does not change any of the results or conclusions of our work. The particular tumour volume/cell number used for our modelling is not of immediate importance for our analyses, as we do not address patient-specific predictions. Lastly, we noticed incorrectly labelled figure panels, possibly due to an error during proof stage: In figure 2, panels (a) and (b), the units on the y-axes should be μl−1, not ml−1.
AB - The published manuscript ‘The roles of T-cell competition and stochastic extinction events in chimaeric antigen receptor T-cell therapy’. [1] requires a correction. For the calculation of initial tumour size, we used data from the literature, specifically as reported by Dean et al. [2]. We inadvertently cited the wrong source (‘[5]’ in the originally published manuscript), which might be of importance for readers in two places in our manuscript. First, in the caption for figure 1, panel (c), on page 3: Median initial tumour mass was 94.86 ml; this median value originates from the combined cohort previously published in Dean et al. [1]. Only 22 patients of this dataset (out of 96) were on the Zuma-1 trial. All others received commercial CAR T cell therapy. Second, in the bottom line of table 1, on page 4, for ‘initial median tumour cell number’, the reference in the last column should have cited the additional reference Dean et al. [2]. Of note, this error does not change any of the results or conclusions of our work. The particular tumour volume/cell number used for our modelling is not of immediate importance for our analyses, as we do not address patient-specific predictions. Lastly, we noticed incorrectly labelled figure panels, possibly due to an error during proof stage: In figure 2, panels (a) and (b), the units on the y-axes should be μl−1, not ml−1.
UR - http://www.scopus.com/inward/record.url?scp=85124286064&partnerID=8YFLogxK
U2 - 10.1098/rspb.2021.2786
DO - 10.1098/rspb.2021.2786
M3 - Comment/debate
C2 - 35135356
AN - SCOPUS:85124286064
SN - 0962-8452
VL - 289
JO - Proceedings of the Royal Society B: Biological Sciences
JF - Proceedings of the Royal Society B: Biological Sciences
IS - 1968
M1 - 20212786
ER -